JMKX000197

JMKX000197 is a small molecule drug developed by Jemincare Therapeutics for the treatment of malignant pleural effusion and non-muscle invasive bladder cancer, particularly in BCG-unresponsive cases. It is currently in Phase 1 clinical trials, with studies evaluating its safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy. Preclinical research suggests that JMKX000197 can regulate the immune system and exhibits significant anti-tumor effects in animal models resistant to BCG therapy[1][2][6][7]. The drug is administered as an injection. Mechanism of action has not been disclosed in public sources as of April 2025. The drug’s development focuses on oncology indications where immune modulation may be relevant.